The Role of [18F]-2-fluoro-2-deoxy-d-glucose-positron Emission Tomography in Thyroid Nodules with Indeterminate Fine-needle Aspiration Biopsy: Systematic Review and Meta-analysis of the Literature
Overview
Authors
Affiliations
Indeterminate results at fine-needle aspiration biopsy (FNAB) of thyroid nodules pose a clinical dilemma, because only 20% to 30% of patients suffer from malignancy. Previous studies suggested that the false-negative ratio of [(18)F]-2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) is very low; therefore, it may help identify patients who would benefit from (hemi)thyroidectomy. A systematic literature search was performed in 5 databases. After assessment, the identified studies were analyzed for heterogeneity, and the extracted data of test characteristics were pooled using a random-effects model. Threshold effects were examined, and publication bias was assessed. The query resulted in 239 records, of which 6 studies met predefined inclusion criteria. Data from 225 of the 241 described patients could be extracted. There was mild to moderate heterogeneity in study results (inconsistency index [I(2)] = 0.390-0.867). The pooled prevalence of malignancy was 26%. Pooled sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 95% (95% confidence interval [95% CI], 86%-99%), 48% (95% CI, 40%-56%), 39% (95% CI, 31%-47%), 96% (95% CI, 90%-99%), and 60% (95% CI, 53%-67%), respectively. Sensitivity increased to 100% for the 164 lesions that measured >15 mm in greatest dimension. There was no evidence of threshold effects or publication bias. A negative FDG-PET scan in patients who had thyroid nodules >15 mm with indeterminate FNAB results excluded thyroid cancer in a pooled population of 225 patients. Conversely, a positive FDG-PET result did not identify cancer, because approximately 50% of these patients had benign nodules. The authors concluded that the incorporation of FDG-PET into the initial workup of such patients before surgery deserves further investigation.
Ren X, Zhang J, Song Z, Li Q, Zhang D, Li X Front Oncol. 2024; 14:1357419.
PMID: 38863637 PMC: 11165073. DOI: 10.3389/fonc.2024.1357419.
Integrated Diagnostics of Thyroid Nodules.
Giovanella L, Campenni A, Tuncel M, Petranovic Ovcaricek P Cancers (Basel). 2024; 16(2).
PMID: 38254799 PMC: 10814240. DOI: 10.3390/cancers16020311.
Molecular testing raises thyroid nodule fine needle aspiration diagnostic value.
Han D, Min D, Xie R, Wang Z, Xiao G, Wang X Endocr Connect. 2023; .
PMID: 37310413 PMC: 10448596. DOI: 10.1530/EC-23-0135.
Singh R, Gupta V, Kumar A, Singh K Adv Pharmacol Pharm Sci. 2023; 2023:9993386.
PMID: 36911357 PMC: 9998157. DOI: 10.1155/2023/9993386.
Vriens D, de Koster E, de Geus-Oei L, Oyen W Eur J Nucl Med Mol Imaging. 2023; 50(4):975-979.
PMID: 36658413 DOI: 10.1007/s00259-022-06093-0.